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The usefulness of an 18F-FDG-PET/MR 
examination in a patient with rectal  
and breast cancer. A case report
ABSTRACT
Recently, we have gained access to innovative radiological and metabolic examination methods. One of these meth-
ods is PET/MRI with fluorodeoxyglucose (18F-FDG) tracer. Performing this innovative examination in a 69-year-old 
woman with diagnosed rectal cancer brought additional benefits. The use of PET/MRI resulted in precise clinical 
staging, the detection of a synchronous early-stage right breast cancer, and in the optimisation of treatment of 
both cancers. To date, diagnostic guidelines concerning rectal and breast cancers do not recommend the use 
of functional imaging for routine imaging.
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Introduction
New imaging methods make diagnostics more 
precise and help us diagnose illnesses at an earlier 
stage, which in turn increases the chances of curing 
the patient. One of the innovative diagnostic tools is 
a hybrid technique — MRI combined with PET. One 
of the main advantages of this technology is its ability 
to morphologically image the whole body while also 
imaging its metabolism by means of PET with the 
fluorodeoxyglucose isotope 18F. It is worth noting 
that the classic PET/CT method uses a diagnostically 
sub-optimal low-dose cone beam tomography, whereas 
in PET/MRI the magnetic resonance images are of high 
quality, with T1 sequences with and without contrast, 
T2, and diffusion weighted imaging.
Case report
A 69-year-old patient in good general condition 
WHO-0, was referred to the Oncology Centre of 
Bialystok due to rectal cancer. A tumour was found 
during ordinary colonoscopy. The histopathological 
material obtained during the examination showed an 
intestinal type of adenocarcinoma. The patient had 
smoked about 10 cigarettes per day for 20 years and 
suffered from hypertension. She had a family record 
of breast cancer with her sister. The patient reported 
no problems. In the clinical examination the rectal 
tumour was beyond reach during rectal exam. CT 
showed a rectal tumour located about 3 cm behind 
the anal sphincter, infiltrating the mesorectum and 
possibly metastatic regional lymph nodes. About 12 cm 
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from the sphincter colonoscopy visualised a stiff, exo-
phytic infiltration, bleeding on contact, narrowing the 
lumen to an extent that prevented further insertion 
of the apparatus. The patient was then preliminarily 
qualified for neoadjuvant radiochemotherapy with 
delayed surgery time. 
The patient also underwent a PET/MRI examina-
tion, using a 3T Biograph mMR Siemens® device with 
18F-FDG tracer. The examination showed irregular 
thickening of the rectal wall to 14 mm over 72 mm, 
starting at about 50 mm above anal sphincter, with 
increased FDG uptake at SUVmax = 15.9. The fat 
planes around the visualised tumour were effaced 
but no infiltration to surrounding organs was found. 
The local lymph nodes: pararectal, parasigmoid, and 
presacral did not exceed 7 mm in diameter in the MRI 
examination, and no increased FDG uptake was found 
in PET. Moreover, T2- and T1-weighted images showed 
a somewhat well-limited focal lesion sized 20 × 18 mm 
of spicular outline with slightly increased FDG uptake 
— SUVmax = 2.2 in the right breast, in the lower internal 
quadrant, and a swollen lymph node under the right arm, 
sized 11 × 7 mm with a slightly increased FDG uptake at 
SUVmax = 0.78. Clinical examination showed no breast 
tumour nor any swollen axillary lymph nodes. The pa-
tient, due to her earlier family history, avoided screening 
tests for breast cancer. 
Following further assessment of the clinical stage 
of the disease (which included the results of PET/MRI 
examination) it was decided that a new form of therapy 
should be adopted. The patient underwent 3D radio-
therapy of X15 MV for the rectal tumour, mesorectum, 
and regional lymph nodes up to a total dose of 25 Gy 
in five fractions, then she underwent a surgical frontal 
rectal resection. During her stay at the Oncological Sur-
gery Department, the patient underwent a core needle 
biopsy of the suspicious right breast tumour, which was 
visualised in PET/MRI, in order to collect diagnostic 
material for histopathological examination. 
The postoperative histopathological examination 
from the rectum showed an ulcerated tumour taking up 
nearly the entire perimeter of the intestinal wall over 
a 4-cm segment. The transverse cross-section showed 
a whitish infiltration, which macroscopically included 
the subcutaneous tissue surrounding the rectum. Mor-
phologically, a G2 adenocarcinoma with a mucous 
component — ypT3 — was diagnosed. All (15) lymph 
nodes of the mesorectum were inflamed. In the mate-
rial obtained during the core-needle biopsy of the right 
breast, invasive duct carcinoma with a malignancy 
level at G2 was characterised by oestrogen receptor 
expression in 97% of the cancer cells, progesterone 
receptor expression in less than 1% of the cells, lack of 
HER2 expression, and the presence of Ki-67 protein 
Figure 1. PET/MRI scan using a 3T Biograph mMR Siemens® with 18F-FDG. The images show rectal carcinoma (arrow), respectively: 
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Figure 2. PET scan with tracer 18F-FDG — metabolic imaging of the rectal carcinoma. The arrow points to the area of increased 
FDG uptake in the tumour, SUV — 15.9
Figure 3. PET/MRI scan using a 3T Biograph mMR Siemens® with 18F-FDG. The images show breast cancer (the arrow), respectively: 
A. MRI in T1-weighted sequence; B. the fusion of MRI images in T2-weighted sequence and PET
A B
A B
in 45% of the cells. In the material obtained during 
a USG-guided fine-needle biopsy of the right axillary 
lymph node visualised in PET/MRI, cells suspected 
of malignancy were found. The patient underwent 
a breast-conserving surgery and sentinel lymph node 
(SLN) procedure. Pathological postoperative breast 
material showed a white irregular tumour, with uneven 
boundaries, sized: 2.3 × 2 cm. Microscopically the image 
corresponded to invasive G2, pT2 carcinoma. In one of 
the seven sampled axillary lymph nodes a macrometas-
tasis of the breast cancer was found. Next, the patient 
received adjuvant chemotherapy based on epirubicin 
and cyclophosphamide (four courses), then radical 3D 
radiotherapy X6/15 MV for the right breast and right 
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Figure 5. CT localising examination, no contrast. The images 
show rectal carcinoma (the arrow) in: A. the sagittal plane; 




axillary lymph nodes up to the total dose of 45 Gy ad-
ministered in 20 fractions. The dose was increased to 
the postoperative site after the excised breast tumour at 
16 Gy in eight fractions. Radiotherapy was completed in 
March 2018. The patient is now undergoing hormonal 
therapy with letrozole. 
Discussion
MRI examination has been used for many years 
now in preoperative evaluation of rectal carcinoma 
progression [1]. MRI makes it possible to better assess 
the risk of infiltration of the circular surgical margin, 
to better match and optimise therapies, and to single 
out the group of patients who do not need preopera-
tive treatment [2]. The guidelines of the Polish Society 
of Clinical Oncology regarding evaluation of the local 
stage of rectal carcinoma suggest MRI examination of 
the lesser pelvis and transrectal USG [2]. Additionally, 
it is recommended that the thoracic cavity, abdominal 
cavity, and the pelvis [2] be CT scanned. In patients with 
rectal cancer, PET scan is not recommended routinely 
in the diagnostic process but only when a local relapse 
is suspected [2]. In the National Comprehensive Cancer 
network (NCCN) guidelines, a pelvic MRI with contrast 
is mandatory unless there are contraindications for the 
examination, e.g. an implanted heart pacer. PET/CT is 
recommended only in patients with confirmed disease 
spread with potentially resectable metastases [3]. Scien-
tific publications do not report any significant informa-
tion on the use of PET in the primary evaluation of rectal 
cancer; however, there is a lot of research confirming the 
effectiveness of PET at verifying the presence of metas-
Figure 4. PET scan using a 3T Biograph mMR Siemens® with 18F-FDG — metabolic imaging of the breast cancer. The arrow 
points to an area of increased FDG uptake in the tumour, SUV — 2.2
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tases in regional lymph nodes (sensitivity and specificity 
are, respectively, 56.8% and 90.3%) [4], or at confirming 
the spread of cancer (sensitivity and specificity respec-
tively — 91% and 76%) [5]. Similarly, PET examina-
tion is not a standard tool in breast cancer diagnostics; 
however, research suggests that it is very sensitive and 
specific in diagnosing this type of cancer — respectively, 
97% and 80% [6], for lymph nodes — 46.3% and 91.1% 
and distant metastases of this cancer — 86–100% 
and 90–98% [7]. MRI with contrast is used in breast 
diagnostic procedures more often. In a large group of 
women (n = 2995) with intermediate and high risk of 
breast cancer, using this method resulted in finding just 
27 new cases of cancer. However, it was characterised 
by a better sensitivity than ultrasonography (USG) or 
mammography (their sensitivity was, respectively: 86%, 
58%, and 57%) [8]. In the presented case, the results 
of colonoscopy, CT, and PET/MRI were different with 
respect to the distance of the rectal tumour from the anal 
sphincter. The distance was respectively 12 cm, 3 cm, 
and 5 cm. The literature reports differences of this sort 
between MRI and colonoscopy [9]. They can amount to 
–3 to +8 cm [9]. It is likely to be caused by the lack of 
agreement between endoscopists regarding the proper 
technique of measuring the distance between the rectal 
tumour and the sphincter [9]. Jacobs at al. emphasise 
that in order to assess the distance between the rectal 
tumour and the sphincter an MRI examination should 
be performed [9]. Proper evaluation of the stage of the 
disease and the location of the rectal tumour in respect 
to the anal sphincter is crucial for the possibility of 
surgical intervention that could spare that sphincter, 
thus preserving of the continuity of digestive tract and 
consequently the quality of life of the patient after the 
treatment is finished [10]. Owing to precise, effective 
MRI imaging in PET/MRI in the reported case, it was 
possible to pinpoint with better precision the depth of 
the intestinal wall infiltration by the rectal carcinoma. 
The PET examination itself helped the patient to evalu-
ate the surrounding lymph nodes, which initially looked 
suspicious in CT images. Re-evaluation of the stage of 
the disease using PET/MRI changed the therapeutic 
regiment from the so-called “long” chemotherapy to 
a short, five-day radiotherapy only. The results obtained 
in PET/MRI were confirmed in pathological examina-
tion in the case of the stage of both the rectal cancer 
(pT3N0) and the breast cancer (pT2N1). Performing 
a PET/MRI scan of the reported patient’s body made it 
possible to detect breast cancer and to effectively treat 
both cancers. There are reports that in women with 
a family history of breast cancer with BRCA mutation 
and without it, using MRI leads to earlier detection of 
intraductal and invasive family or heritable breast cancer 
[11]. PET examination in women from a high-risk group 
of developing breast cancer offers better prospects of 
evaluating the stage of the disease for as many as 34.8% 
of patients and, consequently, it can help change thera-
peutic decisions in 74.1% of cases [12].
Conclusions
Simultaneous application of PET/MRI methods 
facilitates decreasing the time of diagnostics and helps 
optimise the treatment plan. More research is necessary 
to identify the group of patients who will gain clear thera-
peutic benefits from MRI imaging combined with PET. 
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